No description
-
2017 (v1)PublicationUploaded on: April 14, 2023
-
2017 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
Background: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a randomised, controlled phase 3 trial. We used data...
Uploaded on: May 12, 2023 -
2016 (v1)Publication
Baseline neutrophil and derived neutrophil-to-lymphocyte ratio, either alone, or better combined, are significantly and independently associated with progression-free survival and overall survival of metastatic melanoma patients receiving ipilimumab therapy. These factors may serve as objective, inexpensive markers to help risk-group...
Uploaded on: May 13, 2023